1. Home
  2. RYTM vs VRRM Comparison

RYTM vs VRRM Comparison

Compare RYTM & VRRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • VRRM
  • Stock Information
  • Founded
  • RYTM 2008
  • VRRM 1987
  • Country
  • RYTM United States
  • VRRM United States
  • Employees
  • RYTM N/A
  • VRRM N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • VRRM Transportation Services
  • Sector
  • RYTM Health Care
  • VRRM Consumer Discretionary
  • Exchange
  • RYTM Nasdaq
  • VRRM Nasdaq
  • Market Cap
  • RYTM 3.2B
  • VRRM 3.7B
  • IPO Year
  • RYTM 2017
  • VRRM N/A
  • Fundamental
  • Price
  • RYTM $52.70
  • VRRM $20.13
  • Analyst Decision
  • RYTM Strong Buy
  • VRRM Buy
  • Analyst Count
  • RYTM 12
  • VRRM 3
  • Target Price
  • RYTM $68.58
  • VRRM $26.67
  • AVG Volume (30 Days)
  • RYTM 544.5K
  • VRRM 1.4M
  • Earning Date
  • RYTM 05-06-2025
  • VRRM 05-01-2025
  • Dividend Yield
  • RYTM N/A
  • VRRM N/A
  • EPS Growth
  • RYTM N/A
  • VRRM N/A
  • EPS
  • RYTM N/A
  • VRRM 0.19
  • Revenue
  • RYTM $130,126,000.00
  • VRRM $879,207,000.00
  • Revenue This Year
  • RYTM $47.06
  • VRRM $7.98
  • Revenue Next Year
  • RYTM $68.10
  • VRRM $7.13
  • P/E Ratio
  • RYTM N/A
  • VRRM $106.26
  • Revenue Growth
  • RYTM 68.06
  • VRRM 7.57
  • 52 Week Low
  • RYTM $35.17
  • VRRM $19.51
  • 52 Week High
  • RYTM $68.58
  • VRRM $31.03
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 48.00
  • VRRM 30.31
  • Support Level
  • RYTM $52.54
  • VRRM $20.24
  • Resistance Level
  • RYTM $55.21
  • VRRM $21.54
  • Average True Range (ATR)
  • RYTM 2.05
  • VRRM 0.58
  • MACD
  • RYTM 0.36
  • VRRM 0.14
  • Stochastic Oscillator
  • RYTM 47.82
  • VRRM 33.50

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About VRRM Verra Mobility Corporation

Verra Mobility Corp provides smart transportation solutions. The company develops and uses technology and data intelligence to help make transportation safer and easier. It operates in three segments namely Commercial Services, Government Solutions, and Parking Solutions. It generates maximum revenue from the Commercial Services segment. The commercial Services segment delivers tolling and violation management services to rental car companies, commercial fleet vehicle owners, and violation issuing authorities.

Share on Social Networks: